Business Context and Reporting Period
This Form 8-K Current Report was filed by SANUWAVE Health, Inc. on July 28, 2025. The filing discloses the execution of a Separation and Release Agreement with a former executive officer.
Key Financial Metrics
This filing does not contain comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data provided relates to the specific severance package for the departing executive:
- Lump Sum Cash Payment: $97,916.70 (representing five months' annual base salary).
- Pro-rated Bonus: $14,790.81.
- Total Cash Severance: $112,707.51 (subject to applicable federal and state taxes).
Material Changes
The material change reported is the formalization of the departure of Nanci Gilmore, former Chief Commercial Officer. While her termination without cause was previously disclosed as effective May 30, 2025, this filing details the finalized terms of her separation agreement executed on July 28, 2025.
Outlook, Risks, and Unusual Items
Management Commentary and Terms:
- Equity Vesting: Ms. Gilmore's employee stock options will continue to vest through January 31, 2026 and remain exercisable until their respective expiration dates.
- Legal Protections: The agreement includes a release of claims in favor of the Company, along with customary confidentiality and non-disparagement provisions.
- Risks: The filing does not disclose new operational risks or contingencies beyond the standard executive transition.
Investor Verification Checklist
- Verify the impact of the Chief Commercial Officer departure on the company's commercial strategy and sales pipeline.
- Review the full text of the Separation and Release Agreement (Exhibit 10.1) for any additional non-compete or non-solicit clauses not summarized in the 8-K.
- Monitor future filings for the actual cash outflow related to the $112,707.51 severance payment.
- Check subsequent 10-Q or 10-K filings for the accounting treatment of the accelerated or continued vesting of stock options.